Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q96NL8
UPID:
CF418_HUMAN
Alternative names:
-
Alternative UPACC:
Q96NL8; F4Y588
Background:
Cilia- and flagella-associated protein 418 plays a crucial role in photoreceptor outer segment disk morphogenesis, suggesting its pivotal involvement in the structural integrity and function of photoreceptors. This protein's significance is underscored by its association with vital visual processes.
Therapeutic significance:
The protein is directly implicated in several inherited retinal dystrophies, including Cone-rod dystrophy 16, Retinitis pigmentosa 64, and Bardet-Biedl syndrome 21. These associations highlight its potential as a target for therapeutic intervention, aiming to alleviate or halt the progression of these debilitating visual impairments.